Pyrazinamide News and Research

RSS

Inhibiting immune response during initial multi-drug therapy could speed TB treatment time

Inhibiting a key immune response in mice during initial multi-drug treatment for tuberculosis could - paradoxically - shorten treatment time for the highly contagious lung infection according to new research from Johns Hopkins Children's Center and the Center for TB Research.

29 Jun 2012

TB research finds body’s own response helps TB bacteria survive

Inhibiting a key immune response in mice during initial multi-drug treatment for tuberculosis could — paradoxically — shorten treatment time for the highly contagious lung infection according to new research from Johns Hopkins Children’s Center and the Center for TB Research. Shorter duration of drug therapy is key, researchers say, to increase treatment compliance for the growing global health threat posed by the disease.

28 Jun 2012

TB Alliance launches new combination drug trial

In an ambitious effort to stem the dangerous tide of tuberculosis (TB) and deadly drug-resistant TB around the world, TB Alliance today announced that it has launched a first-of-its-kind clinical trial to test a novel drug combination – in both patients who have TB and those who have multidrug-resistant TB (MDR-TB).

19 Mar 2012

Research into TB medication may shorten treatment regimen

Research of the common tuberculosis (TB) drug pyrazinamide, which is used in combination with other medications to treat the disease in a six-month regimen, "has now revealed that the drug does kill the latent form of the microbe, which does not cause observable symptoms," VOA News reports.

23 Aug 2011

Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis

For nearly 60 years, Pyrazinamide (PZA) has been used in conjunction with other medications to treat tuberculosis (TB), but scientists did not fully understand how the drug killed TB bacteria. PZA plays a unique role in shortening the duration of current TB therapy to six months and is used frequently to treat multi-drug resistant TB.

12 Aug 2011

Researchers discover key reason why pyrazinamide shortens duration of TB therapy

Pyrazinamide has been used in combination with other drugs as a first-line treatment for people with tuberculosis (TB) since the 1950s, but exactly how the drug works has not been well understood.

12 Aug 2011

Mayo Clinic licenses M. tuberculosis complex speciation test from QIAGEN

Mayo Clinic has licensed patent rights from QIAGEN to enable Mayo Medical Laboratories to offer an M. tuberculosis complex speciation test. The test expands Mayo Medical Laboratories' current offering for tuberculosis testing, which already includes M. tuberculosis complex culture, molecular identification and drug susceptibility testing.

From QIAGEN Manchester Limited 19 Jul 2011

Immunitor completes V5 Phase IIb imm01 clinical trial enrollment for TB

Immune Network Ltd., advises that its potential acquisition, Immunitor USA Inc., has announced the completion of enrollment in its Phase IIb imm01 clinical trial of V5 in tuberculosis.

15 Nov 2010

TB Alliance launches three-drug combination trial for drug-sensitive and multidrug-resistant TB

In advance of the 41st Union World Conference, the Global Alliance for TB Drug Development (TB Alliance) today announced the launch of the first clinical trial to test a novel tuberculosis regimen in a new development paradigm designed to speed new treatments to patients. This novel three-drug combination shows promise to treat both drug-sensitive (DS-TB) and multidrug-resistant TB (MDR-TB), and alter the course of the TB pandemic by shortening and simplifying treatment worldwide.

8 Nov 2010

Philippine FDA's LSD attains ISO/IEC 17025:2005 accreditation for testing and calibration laboratories

In an effort that will contribute to raising the quality of medicines in the Philippines and surrounding regions, the Laboratory Services Division (LSD) of the Philippine Food and Drug Administration (FDA) has attained the internationally recognized accreditation for testing and calibration laboratories, International Organization for Standardization/ International Electrotechnical Commission (ISO/IEC) 17025:2005.

13 Jul 2010

Higher drug doses needed to defeat tuberculosis in overweight and obese

The typical dose of a medication considered pivotal in treating tuberculosis effectively is much too low to account for modern-day physiques, UT Southwestern Medical Center researchers said.

30 Jul 2009

Slow-growing tuberculosis bacteria point the way to new drug development

The discovery of a large number of slow-growing Mycobacterium tuberculosis bacteria, which cause tuberculosis (TB), in the lungs of TB patients could be an important step forward in the design of new anti-TB drugs.

30 Mar 2009

Rifapentine is back for tuberculosis

It has no current market, not even a prescription price. Its makers stopped commercial production years ago, because demand was so low.

18 Dec 2007

Moxifloxacin drug combo speeds up treatment of tuberculosis

A team of tuberculosis (TB) experts at Johns Hopkins and in Brazil have evidence that substituting the antibiotic moxifloxacin in the regimen of drugs used to treat the highly contagious form of lung disease could dramatically shorten the time needed to cure the illness from six months to four.

18 Sep 2007

Tuberculosis therapy in HIV-infected patients

In a retrospective study of 700 patients with culture-positive tuberculosis (TB), relapse rates were found to be significantly higher in HIV-infected patients compared to HIV-uninfected patients following a rifamycin-based regimen.

3 Jun 2007

WHO adds four anti-tuberculosis medicines to its list of prequalified medicines

The World Health Organization (WHO) has added four anti-tuberculosis medicines to its list of prequalified products.

25 Mar 2007

The incidence, distribution, and control of tuberculosis

A reduction in tuberculosis (TB) incidence, prevalence and death rate can be achieved by 2015 in most parts of the world, with the greatest challenges occurring in Africa and Eastern Europe, according to a projection by the Stop TB Department of the World Health Organization.

1 Mar 2006

New combination treatment that could dramatically shorten the length of tuberculosis treatment

The clinical results of a new combination treatment that could dramatically shorten the length of tuberculosis treatment were presented at a recent scientific conference in the USA. This virulent disease of the lungs still infects millions every year, with a notable resurgence in Europe, especially in the East.

10 Jan 2006

Scientists have identified a novel anti-tuberculosis (TB) compound

Scientists at Johnson & Johnson Pharmaceutical Research and Development have identified a novel anti-tuberculosis (TB) compound that works better and faster than the current standard of care in mouse models of TB infection.

14 Dec 2004